• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Collegium Pharma (NQ: COLL )

    32.18 -0.18 (-0.56%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 180,471
    Open 32.15
    Bid (Size) 29.10 (1)
    Ask (Size) 33.87 (1)
    Prev. Close 32.36
    Today's Range 31.88 - 32.33
    52wk Range 20.83 - 40.95
    Shares Outstanding 32,715,322
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Dr. Reddy's Labs Stock Sees Improved Technical Strength
    On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76. 
    Via Investor's Business Daily
    7 Biotech Stocks to Buy on the Dip: June 2024
    With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
    Via InvestorPlace

    Performance

    YTD
    +3.04%
    +3.04%
    1 Month
    +1.48%
    +1.48%
    3 Month
    -19.53%
    -19.53%
    6 Month
    -0.37%
    -0.37%
    1 Year
    +50.44%
    +50.44%

    More News

    Read More
    NASDAQ:COLL appears to be flying under the radar despite its strong fundamentals.
    Via Chartmill
    Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Demystifying Collegium Pharmaceutical: Insights From 4 Analyst Reviews
    Via Benzinga
    Critical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To Know
    Via Benzinga
    Where Collegium Pharmaceutical Stands With Analysts
    Via Benzinga
    Collegium to Participate in Jefferies Global Healthcare Conference
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium Announces $35 Million Accelerated Share Repurchase Program
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Recap: Collegium Pharmaceutical Q4 Earnings
    Via Benzinga
    Analyst Expectations For Collegium Pharmaceutical's Future
    Via Benzinga
    Why Collegium Pharmaceutical Shares Are Gaining Today
    Via Benzinga
    Collegium Reports First Quarter 2024 Financial Results
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium Announces CEO Transition
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Collegium Provides 2024 Financial Guidance
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Collegium Announces $25 Million Accelerated Share Repurchase Program
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.